Sinteses e caracterização de zeólitas para imobilização da lipase de Thermomyces lanuginous aplicada a produção de biodiesel a partir de óleo de palma via rota etílica

Pós-graduação em Microbiologia - IBILCE

Seleção de microrganismos celulolíticos, imobilização e aplicação das celulases, produzidas e comercial, na hidrólise da celulose

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Desenvolvimento de novas tecnologias para produção de xarope de glicose a partir do amido

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Produção de biodiesel etílico com uso de lipases extracelulares de fungos termofílicos

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Produção de lipases por fungos termofílicos e mesofílicos e uso na produção de biodiesel etílico

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Desenvolvimento de um biosensor amperométrico para a detecção do vírus da Hepatite C

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Desenvolvimento de sensor biomimético para detecção de resíduos de pesticidas organofosforados e carbamatos em alimentos

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Imobilização multipontual covalente de xilanases: seleção de derivados ativos e estabilizados

Pós-graduação em Biotecnologia - IQ

'Beta'-D-frutofuranosidases de Fusarium graminearum: produção, purificação, imobilização e determinação das propriedades bioquímicas de enzimas solúveis e secas em Spray dryer

Pós-graduação em Biotecnologia - IQ

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network

Mucopolysaccharidosis type I (MPS I) is a rare lysosomal disorder caused by deficiency of alpha-L-iduronidase. Few clinical trials have assessed the effect of enzyme replacement therapy (ERT) for this condition. We conducted an exploratory, open-label, non-randomized, multicenter cohort study of patients with MPS I. Data were collected from questionnaires completed by attending physicians at the time of diagnosis (T1; n = 34) and at a median time of 2.5 years later (T2; n = 24/34). The 24 patients for whom data were available at T2 were allocated into groups: A, no ERT (9 patients; median age at T1 = 36 months; 6 with severe phenotype); B, on ERT (15 patients; median age at T1 = 33 months; 4 with severe phenotype). For all variables in which there was no between-group difference at baseline, a delta of ≥ ± 20% was considered clinically relevant. The following clinically relevant differences were identified in group B in T2: lower rates of mortality and reported hospitalization for respiratory infection; lower frequency of hepatosplenomegaly; increased reported rates of obstructive sleep apnea syndrome and hearing loss; and stabilization of gibbus deformity. These changes could be due to the effect of ERT or of other therapies which have also been found more frequently in group B. Our findings suggest MPS I patients on ERT also receive a better overall care. ERT may have a positive effect on respiratory morbidity and overall mortality in patients with MPS I. Additional studies focusing on these outcomes and on other therapies should be performed.

Mucopolysaccharidoses in northern Brazil: targeted mutation screening and urinary glycosaminoglycan excretion in patients undergoing enzyme replacement therapy

Mucopolysaccharidoses (MPS) are rare lysosomal disorders caused by the deficiency of specific lysosomal enzymes responsible for glycosaminoglycan (GAG) degradation. Enzyme Replacement Therapy (ERT) has been shown to reduce accumulation and urinary excretion of GAG, and to improve some of the patients' clinical signs. We studied biochemical and molecular characteristics of nine MPS patients (two MPS I, four MPS II and three MPS VI) undergoing ERT in northern Brazil. The responsiveness of ERT was evaluated through urinary GAG excretion measurements. Patients were screened for eight common MPS mutations, using PCR, restriction enzyme tests and direct sequencing. Two MPS I patients had the previously reported mutation p.P533R. In the MPS II patients, mutation analysis identified the mutation p.R468W, and in the MPS VI patients, polymorphisms p.V358M and p.V376M were also found. After 48 weeks of ERT, biochemical analysis showed a significantly decreased total urinary GAG excretion in patients with MPS I (p < 0.01) and MPS VI (p < 0.01). Our findings demonstrate the effect of ERT on urinary GAG excretion and suggest the adoption of a screening strategy for genotyping MPS patients living far from the main reference centers.

Substâncias húmicas: extração, caracterização, novas perspectivas e aplicações

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Padronização e aplicação da técnica de ELISA (Enzyme-linked immunosorbent assay) indireto com anticorpo de captura para a detecção de anticoepos contra o cicovírus suíno tipo 2

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Imobilização de lipase po diferentes técnicas para obtenção de catalizadores estáveis

Pós-graduação em Biologia Geral e Aplicada - IBB

Imobilização de lipases por adsorção e ligação covalente em derivados de agarose e quitosana e sua aplicação em biocatálise

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)